Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results

Blood. 2017 Oct 12;130(15):1768-1771. doi: 10.1182/blood-2017-02-765032. Epub 2017 Aug 21.

Srdan Verstovsek¹, Francesco Passamonti², Alessandro Rambaldi^{3

4}, Giovanni Barosi⁵, Elisa Rumi^{6

7}, Elisabetta Gattoni⁸, Lisa Pieri^{9

10}, Huiling Zhen¹¹, Muriel Granier¹¹, Albert Assad¹¹, Mario Cazzola^{6

7}, Hagop M Kantarjian¹, Tiziano Barbui¹², Alessandro M Vannucchi^{9

10}

¹ Department of Leukemia, MD Anderson Cancer Center, University of Texas, Houston, TX.
² Department of Medicine and Surgery, University of Insubria, Varese, Italy.
³ Hematology and Bone Marrow Transplant Unit, Azienda Ospedaliera Papa Giovanni XXII, Bergamo, Italy.
⁴ Dipartimento di Oncologia ed Emato-Oncologia, University of Milan, Milan, Italy.
⁵ Center for the Study of Myelofibrosis, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo Foundation, Pavia, Italy.
⁶ Department of Molecular Medicine, University of Pavia, Pavia, Italy.
⁷ Department of Hematology Oncology, IRCCS Policlinico San Matteo Foundation, Pavia, Italy.
⁸ Department of Oncology, Ospedale Santo Spirito, Casale Monferrato, Italy.
⁹ Center of Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliera Universitaria Careggi, Florence, Italy.
¹⁰ Department of Experimental and Clinical Medicine, Laboratorio Congiunto for Myeloproliferative Neoplasm, University of Florence, Florence, Italy.
¹¹ Incyte Corporation, Wilmington, DE; and.
¹² Clinical Research Foundation (FROM), Ospedale Papa Giovanni XXIII, Bergamo, Italy.

No abstract available

Publication types